

ABSTRACT OF THE DISCLOSURE

Compounds of formula (I) in which R^1 = C_{1-6} alkyl, optionally halosubstituted; R^2 = H, C_{1-4} alkyl, optionally halosubstituted or replaced by halogen; R^3 = C_{2-4} alkyl, optionally halosubstituted; R^4 = $SO_2NR^5R^6$, CO_2R^7 or halogen, C_{2-4} alkenyl; optionally substituted with NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO^2R^7 or halogen, C_{2-4} alkanoyl, optionally substituted with NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 or halogen; R^5 and R^6 = independently H or C^{1-4} alkyl, or, together with the N atom to which they are attached, a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring optionally substituted with one or two C_{1-4} alkyl groups; R^7 = H, C^{1-4} alkyl, optionally fluorosubstituted, and R^8 = H, C^{1-3} alkyl or hydroxyalkyl with 1 – 4 C atoms, or the pharmaceutically acceptable salts thereof are useful for the chemotherapeutic treatment of neuropathies.